Clinical Considerations in the Management of Individuals at Risk for Hereditary Breast and Ovarian Cancer
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: Hereditary predisposition to breast and ovarian cancer, most commonly due to germline mutations in BRCA1 and BRCA2, has been recognized for many years. The optimal clinical management of individuals with such a predisposition is not yet completely defined. Methods: The current literature regarding the clinical management of individuals at risk for hereditary breast and ovarian cancer was reviewed. Results: Women with germline BRCA1 or BRCA2 mutations are at substantially increased risk for breast and ovarian cancer, although the risks may not be as high as originally reported. Current surveillance options are restricted in their effectiveness by both host and tumor factors as well as limitations of the techniques. Surgical prevention options, while effective, may be complicated by physical or psychological morbidity. Nonsurgical prevention options are under development. Conclusions: The ability to define women as being at hereditary risk for breast and ovarian cancer facilitates the use of specialized surveillance and prevention strategies. Genetic testing, which plays a role in defining risk, requires careful pre- and post-test counseling to discuss the limitations of testing itself and available management strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer Susceptibility and the Functions of BRCA1 and BRCA2
Venkitaraman, A. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00615-3 · Cited by 1,713
Brca1 Controls Homology-Directed DNA Repair
Moynahan, M. E., Chiu, J. W., Koller, B. H., & Jasin, M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80202-6 · Cited by 1,245
Burke, W. (1997) · JAMA · doi:10.1001/jama.277.12.997 · Cited by 955
Efficacy of Bilateral Prophylactic Mastectomy in BRCA1 and BRCA2 Gene Mutation Carriers
Hartmann, L. C., Sellers, T. A., Schaid, D. J., Frank, T. S., Soderberg, C. L., Sitta, D. L., Frost, M. H., Grant, C. S., Donohue, J. H., Woods, J. E., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.21.1633 · Cited by 743
Lakhani, S. R., Jacquemier, J., Sloane, J. P., Gusterson, B. A., Anderson, T. J., van de Vijver, M. J., Farid, L. M., Venter, D., Antoniou, A., Storfer-Isser, A., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.15.1138 · Cited by 707
Stratton, M. R. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10109-4 · Cited by 579
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1
Verhoog, L., Brekelmans, C., Seynaeve, C., van den Bosch, L., Dahmen, G., van Geel, A., Tilanus-Linthorst, M., Bartels, C., Wagner, A., van den Ouweland, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07065-7 · Cited by 452
Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status
Haffty, B. G., Harrold, E., Khan, A. J., Pathare, P., Smith, T. E., Turner, B. C., Glazer, P. M., Ward, B., Carter, D., Matloff, E., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08434-9 · Cited by 307
Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.
Jóhannsson, O. T., Ranstam, J., Borg, A., & Olsson, H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.397 · Cited by 254
Research works printed but not linked: 64
- 10.3322/canjclin.52.1.23 · DOI · Paper page
- 10.1016/S0140-6736(01)06524-2 · DOI · Paper page
- 10.1073/pnas.85.9.3044 · DOI · Paper page
- 10.1126/science.2270482 · DOI · Paper page
- 10.1126/science.7545954 · DOI · Paper page
- 10.1126/science.8091231 · DOI · Paper page
- 10.1038/378789a0 · DOI · Paper page
- 10.1086/301749 · DOI · Paper page
- 10.1016/S1097-2765(01)00174-5 · DOI · Paper page
- 10.1056/NEJM199705153362003 · DOI · Paper page
- 10.1093/jnci/93.16.1215 · DOI · Paper page
- 10.1002/(SICI)1097-0142(20000315)88:6<1393::AID-CNCR17>3.0.CO;2-P · doi:10.1002/(sici)1097-0142(20000315)88:6<1393::aid-cncr17>3.0.co;2-p
- 10.1093/jnci/91.11.943 · DOI · Paper page
- Berchuck A., 1998, Clin Cancer Res., 4, 2433
- 10.1016/S0002-9378(98)70476-4 · DOI · Paper page
- 10.1006/gyno.2001.6430 · doi:10.1006/gyno.2001.6430
- Szabo C.I., 1997, Am J Hum Genet., 60, 1013
- 10.1200/JCO.20.6.1480 · doi:10.1200/jco.20.6.1480 · Paper page
- 10.1136/jmg.38.12.824 · DOI · Paper page
- 10.1038/ng0596-126 · DOI · Paper page
- 10.1016/S0140-6736(96)91484-1 · DOI
- Tonin P., 1995, Am J Hum Genet., 57, 189
- 10.1038/nm1196-1179 · DOI · Paper page
- 10.1086/301903 · DOI · Paper page
- 10.1086/302853 · DOI · Paper page
- 10.1093/jnci/91.24.2112 · DOI · Paper page
- 10.1093/jnci/91.14.1241 · DOI · Paper page
- 10.1016/S0140-6736(05)61821-1 · DOI
- 10.1089/gte.1997.1.41 · doi:10.1089/gte.1997.1.41
- 10.1038/ng1197-341 · DOI · Paper page
- 10.1038/ng0596-117 · DOI · Paper page
- 10.1086/318181 · DOI · Paper page
- Thompson D., 2002, Cancer Epidemiol Biomarkers Prev., 11, 329
- 10.1093/jnci/91.15.1310 · DOI · Paper page
- 10.1086/318787 · DOI · Paper page
- 10.1016/S0011-3840(01)70035-4 · DOI
- 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W · DOI · Paper page
- 10.1200/JCO.1998.16.5.1642 · DOI · Paper page
- 10.1200/JCO.1999.17.11.3396 · DOI · Paper page
- 10.1200/JCO.2000.18.24.4045 · DOI · Paper page
- Foulkes W.D., 1997, Clin Cancer Res., 3, 2465
- 10.1001/jama.283.17.2260 · DOI · Paper page
- 10.1200/JCO.1999.17.10.3017 · DOI · Paper page
- 10.1200/JCO.2000.18.19.3360 · DOI · Paper page
- 10.1054/bjoc.2000.1239 · DOI · Paper page
- 10.1001/jama.1997.03540360065034 · doi:10.1001/jama.1997.03540360065034 · Paper page
- 10.1023/A:1008389021382 · DOI
- 10.1200/JCO.2001.19.4.924 · DOI · Paper page
- 10.1200/JCO.2002.20.5.1260 · DOI · Paper page
- 10.1148/radiology.215.1.r00ap01267 · DOI · Paper page
- 10.1093/jnci/93.14.1095 · DOI · Paper page
- 10.1200/JCO.2001.19.15.3524 · DOI · Paper page
- 10.1200/JCO.2002.20.6.1570 · doi:10.1200/jco.2002.20.6.1570
- 10.1056/NEJM199901143400201 · DOI · Paper page
- 10.1056/NEJMoa020119 · DOI · Paper page
- 10.1056/NEJMoa012158 · DOI · Paper page
- 10.1093/jnci/91.17.1475 · DOI · Paper page
- 10.1200/JCO.2002.10.101 · DOI
- 10.1056/NEJM199705153362022 · DOI · Paper page
- 10.1016/S0140-6736(00)03258-X · DOI · Paper page
- 10.1001/jama.286.18.2251 · DOI · Paper page
- 10.1056/NEJM199808133390702 · DOI · Paper page
- 10.1056/NEJM200107263450401 · DOI · Paper page
- 10.1016/S0140-6736(00)04642-0 · DOI · Paper page
Cited by
Kirova, Y. M., Stoppa-Lyonnet, D., Savignoni, A., Sigal-Zafrani, B., Fabre, N., & Fourquet, A. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.02.037 · Cited by 129
“BRCA1 and BRCA2 mutations are found in approximately 5% of all breast cancers, and in up to 20–25% in the case of a family history of breast and/or ovarian cancer [9].”
BackgroundKirova, Y. M., Savignoni, A., Sigal-Zafrani, B., de La Rochefordiere, A., Salmon, R. J., This, P., Asselain, B., Stoppa-Lyonnet, D., & Fourquet, A. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0685-6 · Cited by 102
Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
Kotsopoulos, J., Singer, C., & Narod, S. A. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4029-z · Cited by 37
Metadata
- Authors
- Robson, M. E.
- Venue
- Cancer Control
- Publisher
- SAGE Publications
- Published
- 2002-11
- Volume
- 9
- Issue
- 6
- Pages
- 457-465
- ISSN
- 1073-2748 (ISSN-L)
- OpenAlex
- W41647162
- Cited by
- 38
- References
- 9
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.